单剂超低剂量自扩增RNA狂犬病疫苗在小鼠中提供快速完全保护
本研究构建编码狂犬病糖蛋白的自扩增mRNA(saRNA)疫苗,在SPF BALB/c小鼠中评估单剂(0.0008–1 μg)或两剂方案对100 LD₅₀颅内CTN-1攻击的免疫原性和保护效力。单剂0.1 μg在攻击后第14天提供100%存活(第7天为62.5%),两剂(第0天和第7天)将100%保护所需剂量从0.1 μg降至0.02 μg。
要点
- 单剂0.1 μg saRNA疫苗第14天攻击后存活率100%,第7天为62.5%。
- 该有效剂量比既往报告值低15倍。
- 第0天和第7天两剂方案使100%保护所需剂量从0.1 μg降至0.02 μg(降低80%)。
核心结论
- 优化saRNA狂犬病疫苗单剂微克级剂量后14天内实现完全保护,或两剂超低剂量后实现完全保护,优于传统灭活疫苗并提供简化暴露后预防的高效方案。
研究设计与样本
- 构建编码狂犬病糖蛋白的优化saRNA,在SPF BALB/c小鼠中评估单剂(0.0008–1 μg)或两剂方案免疫后对100 LD₅₀颅内CTN-1攻击的免疫原性和保护效力,重点关注免疫后第7天和第14天的早期保护。
主要发现
- 单剂0.1 μg saRNA疫苗在攻击后第14天提供100%存活(第7天为62.5%),并伴随高滴度中和抗体和强T细胞激活。
- 该有效剂量比既往报告值低15倍。
- 第0天和第7天两剂方案使100%保护所需剂量从0.1 μg降至0.02 μg,降低80%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Rabies is a fatal zoonotic disease caused by the Rabies virus (RABV), resulting in approximately 59,000 deaths globally each year. Of these fatalities, 95 % occur in impoverished regions across Asia and Africa where medical resources are scarce, with children accounting for as much as 40 % of the total cases. To address the logistical challenges of current inactivated rabies vaccines-such as the complexities of multi-dose regimens and manufacturing constraints-this study aimed to develop a rabies vaccine based on a self-amplifying mRNA (saRNA) platform, which offers potential advantages in rapid protection, scalable production, and dose-sparing capacity. METHODS: An optimized saRNA encoding the rabies glycoprotein was constructed. In SPF BALB/c mice, immunogenicity and protective efficacy against 100 LD₅₀ intracranial CTN-1 challenge were evaluated after single-dose (0.0008-1 μg) or two-dose regimens, with particular attention to early protection at days 7 and 14 post-immunization. RESULTS: A single administration of 0.1 μg saRNA vaccine delivered 100 % survival upon challenge at day 14 (62.5 % at day 7), accompanied by high-titer neutralizing antibodies and robust T-cell activation. This effective dose is 15-fold lower than previously reported values. A two-dose schedule between day 0 and day 7 further reduced the dose required for 100 % protection by 80 %, from 0.1 μg to 0.02 μg. CONCLUSIONS: The optimized saRNA rabies vaccine achieves complete protection within 14 days after a single microgram-level dose, or after two ultra-low doses, outperforming traditional inactivated vaccines and offering an efficient regimen for simplified post-exposure prophylaxis.
引用
- Zhao D, Chen G, Wang S, et al. A single ultra-low dose self-amplifying RNA rabies vaccine confers rapid and complete protection in mice. Vaccine. 2025. PMID: 41455183. doi:10.1016/j.vaccine.2025.128150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。